The 1.7MW solar system produces energy equivalent to about 10% of the campus’ office building electricity use.
The project is expected to generate about 2.1 million kWh of electricity per year and avoid approximately 1,200 metric tons of carbon dioxide emissions per year.
The facility is the third solar project on the Wilmington campus, with the first two installed in 2004 and 2008.
AstraZeneca is a biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.
